Last reviewed · How we verify

ondansetron (Zofran) — Competitive Intelligence Brief

ondansetron (Zofran) (ondansetron (Zofran)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT3 receptor antagonist. Area: Gastroenterology / Oncology.

marketed 5-HT3 receptor antagonist 5-HT3 receptor Gastroenterology / Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ondansetron (Zofran) (ondansetron (Zofran)) — National Institute on Alcohol Abuse and Alcoholism (NIAAA). Ondansetron blocks serotonin (5-HT3) receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ondansetron (Zofran) TARGET ondansetron (Zofran) National Institute on Alcohol Abuse and Alcoholism (NIAAA) marketed 5-HT3 receptor antagonist 5-HT3 receptor
Trintellix vortioxetine Takeda marketed Serotonin modulator and stimulator (SMS); SSRI-like agent Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor 2013-01-01
Mirtazapine Tablets Mirtazapine Tablets National Institute of Mental Health, Dhaka marketed Tetracyclic antidepressant Alpha-2 adrenergic receptor, 5-HT2 receptor, 5-HT3 receptor
Ramosetron, Aprepitant, Dexamethasone Ramosetron, Aprepitant, Dexamethasone Hallym University Medical Center marketed 5-HT3 antagonist / NK1 antagonist / corticosteroid combination 5-HT3 receptor, NK1 receptor, glucocorticoid receptor
Sancuso patch Sancuso patch LG Life Sciences marketed 5-HT3 receptor antagonist 5-HT3 receptor
ondansetron and dyclonine hydrochloride ondansetron and dyclonine hydrochloride Peking Union Medical College Hospital marketed 5-HT3 receptor antagonist with local anesthetic 5-HT3 receptor; local anesthetic (sodium channel blockade)
Dexamethasone, Ondansetron, Aprepitant Dexamethasone, Ondansetron, Aprepitant Ottawa Hospital Research Institute marketed Antiemetic combination (corticosteroid + 5-HT3 antagonist + NK1 antagonist) Glucocorticoid receptor, 5-HT3 receptor, NK1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT3 receptor antagonist class)

  1. Helsinn Healthcare SA · 4 drugs in this class
  2. LG Life Sciences · 3 drugs in this class
  3. University of Malaya · 2 drugs in this class
  4. GlaxoSmithKline · 1 drug in this class
  5. Hamad Medical Corporation · 1 drug in this class
  6. Eye & ENT Hospital of Fudan University · 1 drug in this class
  7. Instituto Mexicano del Seguro Social · 1 drug in this class
  8. Chongqing University Cancer Hospital · 1 drug in this class
  9. Merck Sharp & Dohme LLC · 1 drug in this class
  10. MonoSol Rx · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ondansetron (Zofran) — Competitive Intelligence Brief. https://druglandscape.com/ci/ondansetron-zofran. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: